ATE74273T1 - Zusammensetzung aus antikoagulantia. - Google Patents

Zusammensetzung aus antikoagulantia.

Info

Publication number
ATE74273T1
ATE74273T1 AT89100852T AT89100852T ATE74273T1 AT E74273 T1 ATE74273 T1 AT E74273T1 AT 89100852 T AT89100852 T AT 89100852T AT 89100852 T AT89100852 T AT 89100852T AT E74273 T1 ATE74273 T1 AT E74273T1
Authority
AT
Austria
Prior art keywords
anticoagulant
anticoagulants
composition
activity
heparin
Prior art date
Application number
AT89100852T
Other languages
English (en)
Inventor
Keizo Hirahara
Original Assignee
Hoechst Japan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11897770&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE74273(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoechst Japan filed Critical Hoechst Japan
Application granted granted Critical
Publication of ATE74273T1 publication Critical patent/ATE74273T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36Blood coagulation or fibrinolysis factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482Serine endopeptidases (3.4.21)
    • A61K38/4866Protein C (3.4.21.69)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424Serine endopeptidases (3.4.21)
    • C12N9/6464Protein C (3.4.21.69)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21Serine endopeptidases (3.4.21)
    • C12Y304/21069Protein C activated (3.4.21.69)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Paper (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
AT89100852T 1988-01-28 1989-01-19 Zusammensetzung aus antikoagulantia. ATE74273T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP63015761A JP2739050B2 (ja) 1988-01-28 1988-01-28 抗血液凝固剤
EP89100852A EP0326014B1 (de) 1988-01-28 1989-01-19 Zusammensetzung aus Antikoagulantia

Publications (1)

Publication Number Publication Date
ATE74273T1 true ATE74273T1 (de) 1992-04-15

Family

ID=11897770

Family Applications (1)

Application Number Title Priority Date Filing Date
AT89100852T ATE74273T1 (de) 1988-01-28 1989-01-19 Zusammensetzung aus antikoagulantia.

Country Status (13)

Country Link
US (1) US5084273A (de)
EP (1) EP0326014B1 (de)
JP (1) JP2739050B2 (de)
KR (1) KR0127754B1 (de)
AT (1) ATE74273T1 (de)
AU (1) AU607303B2 (de)
CA (1) CA1330299C (de)
DE (1) DE68901098D1 (de)
DK (1) DK37789A (de)
ES (1) ES2039709T3 (de)
GR (1) GR3005040T3 (de)
IE (1) IE63528B1 (de)
PT (1) PT89534B (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8822147D0 (en) * 1988-09-21 1988-10-26 Ciba Geigy Ag Pharmaceutically active combination
SE464135B (sv) * 1989-07-14 1991-03-11 Kabivitrum Ab Foerfarande foer bestaemning av funktionell aktivitet av fritt protein s eller protein c i ett plasmaprov
US5571786A (en) * 1990-08-16 1996-11-05 Immuno Aktiengesellschaft Use of protein C or the activation peptide of protein C for preparing a pharmaceutical preparation
AT402260B (de) * 1990-08-16 1997-03-25 Immuno Ag Protein c-hältige pharmazeutische präparation
FR2671973A1 (fr) * 1991-01-25 1992-07-31 Fondation Nale Transfusion San Utilisation de la proteine c activee comme agent anti-agregant plaquettaire.
AT402263B (de) * 1991-06-20 1997-03-25 Immuno Ag Pharmazeutische präparation enthaltend eine thrombolytisch wirkende substanz
EP0651655A4 (de) 1992-07-24 1996-05-29 Oklahoma Med Res Found Blockierung der protein c aktivierung reduziert den blutverlust in mikrogefässen bei chirurgischen eingriffen.
WO1994022471A1 (en) * 1993-04-05 1994-10-13 The Green Cross Corporation Liquid antithrombin iii preparation and method of stabilizing the same
DE4320294A1 (de) * 1993-06-18 1994-12-22 Immuno Ag Verwendung von humanem Protein C zur Verhinderung und Behandlung von Thrombozytenablagerungen
US5516889A (en) * 1993-06-21 1996-05-14 University Technologies International, Inc. Synthetic thrombin receptor peptides
WO1995030429A1 (en) * 1994-05-04 1995-11-16 Board Of Trustees Of The University Of Arkansas Novel ophthalmologic uses of protein c
JPH08224227A (ja) * 1995-02-22 1996-09-03 Internatl Reagents Corp 血液採血管
US6491965B1 (en) * 1995-11-30 2002-12-10 Hamilton Civic Hospitals Research Development, Inc. Medical device comprising glycosaminoglycan-antithrombin III/heparin cofactor II conjugates
US7045585B2 (en) * 1995-11-30 2006-05-16 Hamilton Civic Hospital Research Development Inc. Methods of coating a device using anti-thrombin heparin
US6562781B1 (en) * 1995-11-30 2003-05-13 Hamilton Civic Hospitals Research Development Inc. Glycosaminoglycan-antithrombin III/heparin cofactor II conjugates
US6630137B1 (en) * 1997-04-28 2003-10-07 Eli Lilly And Company Activated protein C formulations
IL132325A (en) * 1997-04-28 2005-07-25 Lilly Co Eli Activated protein c formulations
ID23908A (id) * 1997-06-05 2000-05-25 Lilly Co Eli Metode pengobatan dari penyakit trombosis
GB9711927D0 (en) * 1997-06-09 1997-08-06 Bristol Myers Squibb Co Compositions useful as fibrin sealants
US7204981B2 (en) 2000-03-28 2007-04-17 Eli Lilly And Company Methods of treating diseases with activated protein C
EP1289543A2 (de) 2000-05-24 2003-03-12 Eli Lilly And Company Formulierungen und verfahren zur behandlung von hyperkoagulablen zustäanden
DE10045047A1 (de) 2000-09-12 2002-03-21 Beate Kehrel Arzneimittel enthaltend aktiviertes Antithrombin III
WO2003007686A2 (en) * 2001-07-19 2003-01-30 Dmi Biosciences, Inc. Use of copper chelators to inhibit the inactivation of protein c
WO2003075834A2 (en) * 2002-03-08 2003-09-18 Eli Lilly And Company Activated protein c formulations
WO2009096445A1 (ja) * 2008-01-29 2009-08-06 Kyowa Hakko Kirin Co., Ltd. 神経幹細胞増殖促進剤
WO2024003418A1 (en) 2022-07-01 2024-01-04 Universiteit Maastricht Improved downregulation of histone cytotoxicity by complex of negatively charged polysaccharide and protease

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8319538D0 (en) * 1983-07-20 1983-08-24 Beecham Group Plc Compounds

Also Published As

Publication number Publication date
US5084273A (en) 1992-01-28
PT89534A (pt) 1989-10-04
DK37789A (da) 1989-07-29
DE68901098D1 (de) 1992-05-07
KR0127754B1 (ko) 1998-04-01
AU607303B2 (en) 1991-02-28
CA1330299C (en) 1994-06-21
KR890011606A (ko) 1989-08-21
ES2039709T3 (es) 1993-10-01
EP0326014A1 (de) 1989-08-02
GR3005040T3 (de) 1993-05-24
DK37789D0 (da) 1989-01-27
IE890269L (en) 1989-07-28
PT89534B (pt) 2001-05-31
EP0326014B1 (de) 1992-04-01
JPH01193229A (ja) 1989-08-03
IE63528B1 (en) 1995-05-03
JP2739050B2 (ja) 1998-04-08
AU2885589A (en) 1989-08-03

Similar Documents

Publication Publication Date Title
ATE74273T1 (de) Zusammensetzung aus antikoagulantia.
SE8000470L (sv) Vevnadsbindmedel och forfarande for dess framstellning samt bindmedlets anvendning
DE69008423D1 (de) Dynamische Fixierung von Schweinsaortaklappen.
FI905003A0 (fi) Glykosaminoglykan modifierat protein.
KR870700005A (ko) 하나이상의 활성성분을 함유하는 살충제 조성물
NO166871C (no) Termoplastiske blandinger.
IT8421273A0 (it) Derivati furanici con attivita'antiulcera.
ATE114817T1 (de) Immunologisches nachweisverfahren für herbizide.
DE3871036D1 (de) Leistungsregelung von kombianlagen.
DE68907083D1 (de) Abkoemmlinge von 2-cyclopentenon.
DK191089A (da) Biologisk aktive forbindelser
ATE44640T1 (de) Schaedlingsbekaempfungsmittel.
IT8021337A0 (it) Nuove frazioni di eparina dotate di maggiore attivita' anticoagulante e procedimento per ottenerle.
TR24967A (tr) DIKOTILEDON TüRüNDEN YABANI OTLARA KARSI ETKILI, HERBISIT OLARAK KULLANILACAK GLIOKSIL-SIKLOHEKSEN- DIONLAR.
IL91886A0 (en) Antidote to blood anticoagulants
KR910700061A (ko) 인터로이킨-1β의 안정화 조성물
DE3888543D1 (de) Zusammensetzungen zur herstellung von gasdurchlässigen kontaktlinsen.
ES2125849T3 (es) 1-dimetilcarbamoil-3-sustituido-5-sustituido-1h-1,2,4-triazoles.
ATE57681T1 (de) Carboxanilide.
ATE51520T1 (de) Kosmetikum.
ES2075927T3 (es) Sustancia que se fija a trombina y procedimiento de preparacion.
DE69909010D1 (de) Verwendung von procyanidolischen Oligomeren oder Anthocyanosiden als Anti-Urease Wirkstoffe
DE68913797D1 (de) Verwendung von Paraaminosalicylsäure zur Stabilisierung der enzymatischen Aktivität von Peroxydase in Lösung, Stabilisierungsmittel und Verwendung von stabiliserter Lösung.
IT8721325A0 (it) Procedimento e agente per combattere la tignola crociata della vite.
DE68905178D1 (de) Stabile waessrige zubereitung von aktivem vitamin-d-3.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
RZN Patent revoked